<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:24:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7033174" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7033174</identifier>
        <datestamp>2020-02-28</datestamp>
        <setSpec>scirep</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
              <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
              <journal-title-group>
                <journal-title>Scientific Reports</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-2322</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7033174</article-id>
              <article-id pub-id-type="pmcid">PMC7033174</article-id>
              <article-id pub-id-type="pmc-uid">7033174</article-id>
              <article-id pub-id-type="pmid">32080210</article-id>
              <article-id pub-id-type="publisher-id">58366</article-id>
              <article-id pub-id-type="doi">10.1038/s41598-020-58366-z</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for <italic>TP53</italic> mutant malignancies</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Yudong</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8123-4065</contrib-id>
                  <name>
                    <surname>Janku</surname>
                    <given-names>Filip</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Piha-Paul</surname>
                    <given-names>Sarina</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1377-6070</contrib-id>
                  <name>
                    <surname>Hess</surname>
                    <given-names>Kenneth</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Broaddus</surname>
                    <given-names>Russell</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Lidong</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shi</surname>
                    <given-names>Naiyi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Overman</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kopetz</surname>
                    <given-names>Scott</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6064-6837</contrib-id>
                  <name>
                    <surname>Subbiah</surname>
                    <given-names>Vivek</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Naing</surname>
                    <given-names>Aung</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hong</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tsimberidou</surname>
                    <given-names>Apostolia M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Karp</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yao</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1933-0419</contrib-id>
                  <name>
                    <surname>Fu</surname>
                    <given-names>Siqing</given-names>
                  </name>
                  <address>
                    <email>siqingfu@mdanderson.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Departments of Investigational Cancer Therapeutics, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Departments of Biostatistics, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Departments of Pathology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution>Departments of GI Medical Oncology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, TX USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.452582.c</institution-id><institution>Department of Medical Oncology, </institution><institution> The Fourth Hospital of Hebei Medical University, </institution></institution-wrap>Hebei, Peopleâ€™s Republic of China </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>2</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>20</day>
                <month>2</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>10</volume>
              <elocation-id>3080</elocation-id>
              <history>
                <date date-type="received">
                  <day>6</day>
                  <month>10</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>1</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleâ€™s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleâ€™s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT01339871) or the proteasome inhibitor ixazomib (NCT02042989) in patients with metastatic <italic>TP53</italic> mutant solid tumors. Both trials followed a 3â€‰+â€‰3 dose-escalation design allowing for a dose expansion cohort of up to 14 additional patients with a specific tumor type. Patients had to have a confirmed <italic>TP53</italic> mutation to be enrolled in NCT02042989. Among patients enrolled in NCT01339871, TP53 mutation status was determined for those for whom tumor specimens were available. The results of NCT01339871 were reported previously. Common treatment-related adverse events in NCT02042989 included anemia, thrombocytopenia, fatigue, nausea, vomiting, and diarrhea. Compared with patients with metastatic <italic>TP53</italic> hotspot mutant solid tumors who were treated with ixazomib and vorinostat (nâ€‰=â€‰59), those who were treated with pazopanib and vorinostat (nâ€‰=â€‰11) had a significantly higher rate of clinical benefit, defined as stable disease lasting â‰¥6 months or an objective response (3.4% vs. 45%; <italic>p</italic>â€‰&lt;â€‰0.001), a significantly longer median progression-free survival duration (1.7 months [95% confidence interval (CI), 1.1â€“2.3] vs. 3.5 months [95% CI, 1.7â€“5.2]; <italic>p</italic>â€‰=â€‰0.002), and a longer median overall survival duration (7.3 months [95% CI, 4.8â€“9.8] vs. 12.7 months [95% CI, 7.1â€“18.3]; <italic>p</italic>â€‰=â€‰0.24). Our two phase I trials provide preliminary evidence supporting the use of antiangiogenisis-based therapy in patients with metastatic <italic>TP53</italic> mutant solid tumors, especially in those with metastatic sarcoma or metastatic colorectal cancer.</p>
              </abstract>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Predictive markers</kwd>
                <kwd>Phase I trials</kwd>
                <kwd>Targeted therapies</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100011957</institution-id>
                      <institution>Takeda Pharmaceutical Company Limited | Takeda Oncology</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100008373</institution-id>
                      <institution>Takeda Pharmaceutical Company (Takeda Pharmaceutical Company Limited)</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                      <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30CA016672</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Fu</surname>
                      <given-names>Siqing</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par2">In advanced cancers and those refractory to treatment, many factors may play a contributing role. Tumor cells that survive antiangiogenic therapy and metastasize frequently do so in hypoxic microenvironments<sup><xref ref-type="bibr" rid="CR1">1</xref>â€“<xref ref-type="bibr" rid="CR3">3</xref></sup>. Tumor hypoxia upregulates histone deacetylase (HDAC) activity<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, which modulates the overexpression of hypoxia-inducible factor 1Î± (HIF-1Î±)<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. This hypoxia-mediated increase in HIF-1Î± promotes tumor progression through the HIF-1Î±âˆ’dependent activation of multiple genes, whose expression enables cancer cells to survive, metastasize, and acquire resistance to antiangiogenic therapy<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. HDAC5 is a critical player in the p53 acetylation network<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>, and HDAC6 and HDAC8 interact with heat shock protein 90 to facilitate mutant p53 degradation<sup><xref ref-type="bibr" rid="CR10">10</xref>â€“<xref ref-type="bibr" rid="CR12">12</xref></sup>. HDAC inhibition with vorinostat preferentially kills <italic>TP53</italic> mutant cancer cells in cell cultures and xenograft models<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>.</p>
              <p id="Par3">The enhanced vascular endothelial growth factor (VEGF) pathway plays an important role in the survival and proliferation of cancer cells with <italic>TP53</italic> mutations<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup> and thus represents a potential therapeutic target in <italic>TP53</italic> mutant cancers. In cancer cells, <italic>TP53</italic> mutations are associated with elevated HIF-1Î± levels, which augment the HIF-1Î±âˆ’dependent transcriptional activation of the <italic>VEGF</italic> gene in response to tumor hypoxia<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, and mediate resistance to cancer therapy<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. In addition, we found that among cancer patients receiving VEGF inhibitionâˆ’based therapies, the progression-free survival (PFS) durations of patients with mutated <italic>TP53</italic> were significantly longer than those of patients with wild-type <italic>TP53</italic><sup><xref ref-type="bibr" rid="CR16">16</xref>â€“<xref ref-type="bibr" rid="CR19">19</xref></sup>.</p>
              <p id="Par4">The ability of wild-type p53 protein to induce apoptosis and suppress angiogenesis is of significant scientific merit and urgent clinical interest to develop novel cancer therapeutics. One promising strategy to explore HDAC inhibitor-mediated down-regulation of HIFs for targeting <italic>TP53</italic> mutant tumor resistance to antiangiogenic therapy is supported by both preclinical and retrospective clinical findings<sup><xref ref-type="bibr" rid="CR20">20</xref>â€“<xref ref-type="bibr" rid="CR27">27</xref></sup>. To date, the U.S. Food and Drug Administration has approved pazopanib for the treatment of renal cell carcinoma and soft tissue sarcoma; vorinostat for the treatment of primary cutaneous T-cell lymphoma; and ixazomib for the treatment of multiple myeloma. We therefore conducted two phase I trials: one of the HDAC inhibitor vorinostat plus the VEGF inhibitor pazopanib in patients with advanced malignancies (NCT01339871) and another of vorinostat plus the proteasome inhibitor ixazomib in patients with metastatic <italic>TP53</italic> mutant solid tumors (NCT02042989).</p>
            </sec>
            <sec id="Sec2" sec-type="results">
              <title>Results</title>
              <sec id="Sec3">
                <title>Patient characteristics</title>
                <p id="Par5">The characteristics of the 78 patients enrolled in the phase I trial of pazopanib and vorinostat were reported previously<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. The characteristics of the 59 patients enrolled in the phase I trial of ixazomib and vorinostat are given in TableÂ <xref rid="Tab1" ref-type="table">1</xref>. The phase I trial of ixazomib and vorinostat followed a 3â€‰+â€‰3 dose-escalation design. Patients were enrolled at 4 dose levels. One treatment cycle was 28 days. Oral ixazomib, escalating from 3 to 4â€‰mg, was administered on days 1, 8, and 15, and oral vorinostat, escalating from 100â€‰mg twice daily to 100â€‰mg three times daily, was given on days 1â€“21. The patients enrolled in the ixazomib and vorinostat trial, whose median age was 59 years (range, 24âˆ’76 years), were heavily pretreated; they received a median of 5 systemic therapeutic regimens previously, and 58% had experienced disease progression on VEGF inhibitionâˆ’based therapy.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of patients with confirmed <italic>TP53</italic> mutations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristic</th><th colspan="2">Clinical Trial</th></tr><tr><th>Ixazomibâ€‰+â€‰Vorinostat (nâ€‰=â€‰59)</th><th>Pazopanibâ€‰+â€‰Vorinostat (nâ€‰=â€‰11)</th></tr></thead><tbody><tr><td>Median age (range), years</td><td>59 (24â€“76)</td><td>70 (46â€“78)</td></tr><tr><td colspan="3">Gender</td></tr><tr><td>Â Â Male</td><td>24 (41)</td><td>5 (45)</td></tr><tr><td>Â Â Female</td><td>35 (59)</td><td>6 (55)</td></tr><tr><td colspan="3">Race</td></tr><tr><td>Â Â White</td><td>46 (78)</td><td>9 (82)</td></tr><tr><td>Â Â Hispanic</td><td>5 (8)</td><td>0</td></tr><tr><td>Â Â African American</td><td>4 (7)</td><td>0</td></tr><tr><td>Â Â Asian</td><td>4 (7)</td><td>2 (2)</td></tr><tr><td colspan="3">ECOG performance status score</td></tr><tr><td>Â Â 0</td><td>11 (19)</td><td>0</td></tr><tr><td>Â Â 1</td><td>44 (74)</td><td>11 (100)</td></tr><tr><td>Â Â 2</td><td>4 (7)</td><td>0</td></tr><tr><td colspan="3">Disease type</td></tr><tr><td>Â Â Colorectal cancer</td><td>20 (34)</td><td>3 (27)</td></tr><tr><td>Â Â Ovarian cancer</td><td>14 (23)</td><td>3 (27)</td></tr><tr><td>Â Â Breast cancer</td><td>4 (7)</td><td>1 (9)</td></tr><tr><td>Â Â Sarcoma</td><td>4 (7)</td><td>2 (18)</td></tr><tr><td>Â Â Head and neck cancer</td><td>4 (7)</td><td>1 (9)</td></tr><tr><td>Â Â Others*</td><td>13 (22)</td><td>1 (9)</td></tr><tr><td colspan="3">Prior chemotherapy</td></tr><tr><td>Â Â Median no. of regimens (range)</td><td>5 (0â€“9)</td><td>4 (0â€“10)</td></tr><tr><td>Â Â VEGF inhibitionâˆ’based therapy</td><td>34 (58)</td><td>5 (45)</td></tr><tr><td>Prior radiation therapy</td><td>33 (56)</td><td>3 (27)</td></tr><tr><td>Prior surgery</td><td>47 (80)</td><td>10 (91)</td></tr><tr><td>Median no. of metastasis sites (range)</td><td>3 (1â€“5)</td><td>3 (2â€“5)</td></tr><tr><td><italic>TP53</italic> point mutations</td><td>50 (85)</td><td>9 (82)</td></tr><tr><td><italic>TP53</italic> hotspot mutations<sup>#</sup></td><td>24 (41)</td><td>4 (36)</td></tr><tr><td><italic>TP53</italic> non-point mutations</td><td>9 (15)</td><td>2 (18)</td></tr></tbody></table><table-wrap-foot><p>Note: All data are no. of patients (%) unless otherwise noted.</p><p>Abbreviations: ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor.</p><p>*Includes duodenal, gastric, and pancreatic cancer (nâ€‰=â€‰2 each) and esophageal cancer, endometrial cancer, non-small cell lung cancer, renal cancer, urachal adenocarcinoma, melanoma, and Mullerian tumor (nâ€‰=â€‰1 each).</p><p><sup>#</sup>Mutations at R175, G245, R248, R249, R273, or R282.</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec4">
                <title>Safety evaluation</title>
                <p id="Par6">In the phase I trial of pazopanib and vorinostat, the recommended phase II dosage was 600â€‰mg pazopanib daily in combination with 100â€‰mg vorinostat three times daily<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. In the phase I trial of ixazomib and vorinostat, the recommended phase II dosage was 4â€‰mg ixazomib once daily on days 1, 8, and 15 in combination with 100â€‰mg vorinostat three times daily on days 1âˆ’21 (dose level 4). The clinically significant grade 2 or higher adverse events experienced by patients treated with ixazomib and vorinostat included anemia, thrombocytopenia, fatigue, anorexia, nausea, vomiting, diarrhea, dehydration, and skin rash (Supplementary TableÂ <xref rid="MOESM1" ref-type="media">1</xref>). No treatment-related death or dose-limiting toxicity was observed among these patients. Seven patients, all of whom were enrolled at dose level 4, required dose reductions (18%). The patient withdrawal rates at dose levels 2, 3, and 4 were 13% (1 of 8 patients), 17% (1 of 6 patients), and 31% (12 of 39 patients), respectively.</p>
              </sec>
              <sec id="Sec5">
                <title>Efficacy evaluation</title>
                <sec id="Sec6">
                  <title>Antitumor activity and survival among all patients</title>
                  <p id="Par7">The major clinical outcomes of the 59 patients enrolled in the phase I trial of ixazomib and vorinostat are shown in TableÂ <xref rid="Tab2" ref-type="table">2</xref>. No objective responses were observed in these patients. Compared with patients treated with ixazomib and vorinostat, those treated with pazopanib and vorinostat had a significantly higher rate of clinical benefit, defined as stable disease lasting â‰¥6 months, a partial response, or a complete response (3.4% vs. 19%; <italic>p</italic>â€‰=â€‰0.007) and a significantly longer median PFS duration (1.7 months [95% confidence interval (CI), 1.1â€“2.3] vs. 2.1 months [95% CI, 1.7â€“2.5]; <italic>p</italic>â€‰&lt;â€‰0.001). However, the median OS durations of the patients treated with ixazomib and vorinostat (7.3 months; 95% CI, 4.8â€“9.8) and those treated with pazopanib and vorinostat (8.9 months; 95% CI, 7.0â€“10.8) did not differ significantly (<italic>p</italic>â€‰=â€‰0.34) (Fig.Â <xref rid="Fig1" ref-type="fig">1A,B</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Major Clinical Outcomes in the Phase I Trial of Ixazomib and Vorinostat (nâ€‰=â€‰59).</p></caption><table frame="hsides" rules="groups"><thead><tr><th><italic>TP53</italic> mutation</th><th>Age</th><th>Sex</th><th>Race</th><th>PS</th><th>Pathology</th><th>Dose Level</th><th>Best response</th><th>PFS (mo)</th><th>OS (mo)</th></tr></thead><tbody><tr><td>R273C</td><td>43</td><td>F</td><td>A</td><td>1</td><td>CRC</td><td>1</td><td>PD</td><td>1.0</td><td>3.4+</td></tr><tr><td>R273H</td><td>41</td><td>M</td><td>W</td><td>0</td><td>Gastric</td><td>1</td><td>PD</td><td>1.9</td><td>14.6</td></tr><tr><td>R175H</td><td>64</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>1</td><td>SD</td><td>3.7</td><td>7.2</td></tr><tr><td>Splice site c.376â€“1â€‰Gâ€‰&gt;â€‰A</td><td>59</td><td>F</td><td>W</td><td>1</td><td>SA</td><td>1</td><td>PD</td><td>1.9</td><td>13.3+</td></tr><tr><td>G245S</td><td>64</td><td>M</td><td>AA</td><td>1</td><td>Pancreatic</td><td>1</td><td>PD</td><td>0.6</td><td>1.1</td></tr><tr><td>R248W</td><td>60</td><td>F</td><td>W</td><td>1</td><td>Breast</td><td>1</td><td>PD</td><td>2.0</td><td>6.2</td></tr><tr><td>R196*</td><td>76</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>2</td><td>PD</td><td>1.1</td><td>6.3</td></tr><tr><td>S127F</td><td>67</td><td>F</td><td>W</td><td>1</td><td>Breast</td><td>2</td><td>PD</td><td>0.9</td><td>2.0</td></tr><tr><td>V173M</td><td>55</td><td>F</td><td>W</td><td>1</td><td>Breast</td><td>2</td><td>PD</td><td>1.6</td><td>6.5</td></tr><tr><td>H179P</td><td>58</td><td>M</td><td>H</td><td>0</td><td>CRC</td><td>2</td><td>SD</td><td>3.0</td><td>15.0</td></tr><tr><td>Q104*</td><td>52</td><td>M</td><td>W</td><td>1</td><td>HNC</td><td>2</td><td>Withdrawal</td><td>0.3</td><td>1.3+</td></tr><tr><td>G245S</td><td>56</td><td>F</td><td>W</td><td>2</td><td>Urachal</td><td>2</td><td>PD</td><td>2.1</td><td>18.2</td></tr><tr><td>R342*</td><td>40</td><td>M</td><td>W</td><td>0</td><td>CRC</td><td>2</td><td>PD</td><td>1.9</td><td>13.7</td></tr><tr><td>V10I</td><td>31</td><td>M</td><td>W</td><td>1</td><td>SA</td><td>2</td><td>PD</td><td>1.2</td><td>10.7+</td></tr><tr><td>L111P</td><td>64</td><td>M</td><td>W</td><td>2</td><td>Gastric</td><td>3</td><td>PD</td><td>1.0</td><td>9.7</td></tr><tr><td>R280T</td><td>53</td><td>F</td><td>H</td><td>1</td><td>Breast</td><td>3</td><td>SD</td><td>3.6</td><td>7.2</td></tr><tr><td>R213L</td><td>75</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>3</td><td>PD</td><td>2.0</td><td>29.2+</td></tr><tr><td>A138V</td><td>60</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>3</td><td>PD</td><td>1.0</td><td>1.7</td></tr><tr><td>V272L</td><td>42</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>3</td><td>SD</td><td>3.5</td><td>14.6</td></tr><tr><td>L201*</td><td>64</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>3</td><td>Withdrawal</td><td>2.3</td><td>19.9</td></tr><tr><td>P278A</td><td>63</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>4</td><td>Withdrawal</td><td>1.2</td><td>4.7</td></tr><tr><td>G245S</td><td>38</td><td>M</td><td>AA</td><td>1</td><td>CRC</td><td>4</td><td>PD</td><td>0.9</td><td>2.1</td></tr><tr><td>C135R</td><td>70</td><td>F</td><td>W</td><td>1</td><td>Endometrial</td><td>4</td><td>PD</td><td>1.0</td><td>14.1</td></tr><tr><td>S215N</td><td>57</td><td>M</td><td>W</td><td>1</td><td>HNC</td><td>4</td><td>PD</td><td>1.8</td><td>8.4</td></tr><tr><td>S241F</td><td>51</td><td>M</td><td>AA</td><td>1</td><td>NSCLC</td><td>4</td><td>PD</td><td>2.2</td><td>5.2</td></tr><tr><td>R282W</td><td>60</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>Withdrawal</td><td>1.6</td><td>3.1</td></tr><tr><td>R248W</td><td>60</td><td>F</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>PD</td><td>1.9</td><td>9.1</td></tr><tr><td>R280G</td><td>70</td><td>F</td><td>W</td><td>2</td><td>EOC</td><td>4</td><td>SD</td><td>7.6</td><td>10.2</td></tr><tr><td>R175H</td><td>52</td><td>F</td><td>W</td><td>0</td><td>CRC</td><td>4</td><td>Withdrawal</td><td>1.1</td><td>7.4</td></tr><tr><td>R248Q</td><td>35</td><td>M</td><td>W</td><td>1</td><td>Melanoma</td><td>4</td><td>PD</td><td>0.7</td><td>4.4</td></tr><tr><td>R213*</td><td>48</td><td>F</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>PD</td><td>1.9</td><td>10.8</td></tr><tr><td>C176S, R248Q, R273H</td><td>71</td><td>M</td><td>W</td><td>0</td><td>SA</td><td>4</td><td>SD</td><td>3.9</td><td>18.3</td></tr><tr><td>G244S</td><td>66</td><td>F</td><td>H</td><td>1</td><td>CRC</td><td>4</td><td>PD</td><td>1.5</td><td>10.4</td></tr><tr><td>R273C</td><td>60</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>PD</td><td>1.1</td><td>2.5</td></tr><tr><td>E336Q/ Y234H</td><td>52</td><td>M</td><td>A</td><td>1</td><td>CRC</td><td>4</td><td>Withdrawal</td><td>0.9</td><td>5.8</td></tr><tr><td>C229fs*10</td><td>64</td><td>F</td><td>H</td><td>1</td><td>EOC</td><td>4</td><td>SD</td><td>6.3</td><td>8.6</td></tr><tr><td>E180fs*67</td><td>58</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>4</td><td>PD</td><td>2.1</td><td>5.1</td></tr><tr><td>R248W</td><td>33</td><td>F</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>Withdrawal</td><td>0.6</td><td>7.0</td></tr><tr><td>Y205H</td><td>76</td><td>M</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>PD</td><td>0.5</td><td>2.4</td></tr><tr><td>Q16*/ R248Q</td><td>63</td><td>F</td><td>W</td><td>1</td><td>HNC</td><td>4</td><td>PD</td><td>0.3</td><td>1.1</td></tr><tr><td>R282W</td><td>58</td><td>F</td><td>W</td><td>1</td><td>Mullerian</td><td>4</td><td>SD</td><td>4.1</td><td>11.3</td></tr><tr><td>Y220C</td><td>73</td><td>F</td><td>AA</td><td>2</td><td>EOC</td><td>4</td><td>Withdrawal</td><td>0.9</td><td>2.8+</td></tr><tr><td>R175H</td><td>50</td><td>F</td><td>H</td><td>1</td><td>EOC</td><td>4</td><td>PD</td><td>1.9</td><td>4.9+</td></tr><tr><td>G245R/ K164E</td><td>50</td><td>F</td><td>W</td><td>0</td><td>EOC</td><td>4</td><td>SD</td><td>3.8</td><td>10.8+</td></tr><tr><td>R282W</td><td>24</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>4</td><td>Withdrawal</td><td>0.7</td><td>2.2</td></tr><tr><td>H179Y</td><td>67</td><td>F</td><td>W</td><td>0</td><td>EOC</td><td>4</td><td>PD</td><td>1.8</td><td>8.9+</td></tr><tr><td>R306*</td><td>42</td><td>M</td><td>W</td><td>1</td><td>Renal</td><td>4</td><td>PD</td><td>2.2</td><td>7.9+</td></tr><tr><td>C275F</td><td>64</td><td>F</td><td>A</td><td>1</td><td>CRC</td><td>4</td><td>Withdrawal</td><td>0.5</td><td>6.3+</td></tr><tr><td>R273C</td><td>68</td><td>F</td><td>A</td><td>0</td><td>Pancreatic</td><td>4</td><td>PD</td><td>1.8</td><td>2.5+</td></tr><tr><td>R175H</td><td>56</td><td>F</td><td>W</td><td>1</td><td>Cecum</td><td>4</td><td>Withdrawal</td><td>0.9</td><td>3.7</td></tr><tr><td>R110L</td><td>60</td><td>F</td><td>W</td><td>0</td><td>EOC</td><td>4</td><td>PD</td><td>1.9</td><td>6.6+</td></tr><tr><td>L111P</td><td>73</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>4</td><td>Withdrawal</td><td>1.7</td><td>6.3+</td></tr><tr><td>H179R/R273C</td><td>59</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>4</td><td>Withdrawal</td><td>1.2</td><td>2.8+</td></tr><tr><td>R282W</td><td>46</td><td>F</td><td>W</td><td>1</td><td>CRC</td><td>4</td><td>SD</td><td>4.2</td><td>7.2+</td></tr><tr><td>R273H</td><td>58</td><td>M</td><td>W</td><td>1</td><td>Cecum</td><td>4</td><td>Lost to follow up</td><td>1.1</td><td>2.8</td></tr><tr><td>R273H</td><td>57</td><td>F</td><td>W</td><td>0</td><td>HNC</td><td>4</td><td>Withdrawal</td><td>0.3</td><td>5.7+</td></tr><tr><td>Y234N/R158G</td><td>61</td><td>M</td><td>W</td><td>0</td><td>Esophageal</td><td>4</td><td>PD</td><td>1.9</td><td>4.6+</td></tr><tr><td>V173L</td><td>57</td><td>F</td><td>W</td><td>1</td><td>SA</td><td>4</td><td>PD</td><td>2.5</td><td>3.3+</td></tr><tr><td>P278_G279del</td><td>66</td><td>F</td><td>W</td><td>1</td><td>EOC</td><td>4</td><td>PD</td><td>1.1</td><td>3.5+</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PS, ECOG performance status; PFS, progression-free survival; OS, overall survival; mo, month; M, male; F, female; W, white; A, Asian; H, Hispanic; AA, African-American; PD, progression disease; SD, stable disease;â€‰+â€‰, censored; CRC, colorectal cancer; EOC, epithelial ovarian cancer; SA, sarcoma; HNC, head &amp; neck cancer; NSCLC, non-small cell lung cancer.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>Kaplan-Meier plots of the rates of progression-free survival (PFS; 1A) and overall survival (OS; 1B) of cancer patients treated with pazopanib and vorinostat (nâ€‰=â€‰78) or ixazomib and vorinostat (nâ€‰=â€‰59).</p></caption><graphic xlink:href="41598_2020_58366_Fig1_HTML" id="d29e2747"/></fig></p>
                </sec>
                <sec id="Sec7">
                  <title>Antitumor activity and survival among patients with tp53 hotspot mutations</title>
                  <p id="Par8"><italic>TP53</italic> hotspot mutations were confirmed in all 59 patients enrolled in the phase I trial of ixazomib and vorinostat and in 11 of the 78 patients enrolled in the phase I trial of pazopanib and vorinostat. Compared with patients treated with ixazomib and vorinostat, those treated with pazopanib and vorinostat had a significantly higher rate of clinical benefit (3.4% vs. 45%; <italic>p</italic>â€‰&lt;â€‰0.001) and a significantly longer median PFS duration (1.7 months [95% CI, 1.1â€“2.3] vs. 3.5 months [95% CI, 1.7â€“5.2]; <italic>p</italic>â€‰=â€‰0.002). The median OS duration of the patients treated with pazopanib and vorinostat (12.7 months; 95% CI, 7.1â€“18.3) was longer than that of those treated with ixazomib and vorinostat (7.3 months; 95% CI, 4.8â€“9.8), but this difference was not significant (<italic>p</italic>â€‰=â€‰0.24) (Fig.Â <xref rid="Fig2" ref-type="fig">2A,B</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>Kaplan-Meier plots of the rates of progression-free survival (PFS; 2A) and overall survival (OS; 2B) of patients with metastatic <italic>TP53</italic> mutant solid tumors treated with pazopanib and vorinostat (nâ€‰=â€‰11) or ixazomib and vorinostat (nâ€‰=â€‰59).</p></caption><graphic xlink:href="41598_2020_58366_Fig2_HTML" id="d29e2778"/></fig></p>
                </sec>
                <sec id="Sec8">
                  <title>Antitumor activity and survival among patients with metastatic sarcoma or colorectal carcinoma with TP53 hotspot mutations</title>
                  <p id="Par9">Twenty-four patients enrolled in the phase I trial of ixazomib and vorinostat had colorectal carcinoma (nâ€‰=â€‰20) or sarcoma (nâ€‰=â€‰4) with <italic>TP53</italic> hotspot mutations, and 6 patients enrolled in the phase I trial of pazopanib and vorinostat had colorectal carcinoma (nâ€‰=â€‰3) or sarcoma (nâ€‰=â€‰3) with <italic>TP53</italic> hotspot mutations. Compared with patients treated with ixazomib and vorinostat, those treated with pazopanib and vorinostat had a significantly higher rate of clinical benefit (0% vs. 83%; <italic>p</italic>â€‰&lt;â€‰0.001) and a significantly longer median PFS duration (1.6 months [95% CI, 1â€“2.2] vs. 6.0 months [95% CI, 3.0â€“9.0]; <italic>p</italic>â€‰&lt;â€‰0.001). The median OS duration of the patients treated with pazopanib and vorinostat (19.8 months, 95% CI, 8.2â€“31.4) was longer than that of those treated with ixazomib and vorinostat (8.7 months, 95% CI, 3.4â€“14), but this difference was not significant (<italic>p</italic>â€‰=â€‰0.18) (Fig.Â <xref rid="Fig3" ref-type="fig">3A,B</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>Kaplan-Meier plots of the rates of progression-free survival (PFS; A) and overall survival (OS; B) of patients with metastatic <italic>TP53</italic> mutant sarcoma or colorectal cancer (CRC) treated with pazopanib and vorinostat (nâ€‰=â€‰6) or ixazomib and vorinostat (nâ€‰=â€‰24).</p></caption><graphic xlink:href="41598_2020_58366_Fig3_HTML" id="d29e2814"/></fig></p>
                </sec>
              </sec>
            </sec>
            <sec id="Sec9" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par10">Therapeutic targeting of <italic>TP53</italic> mutations is a rapidly developing field, and various approaches have undergone clinical evaluation<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. We have designed and conducted two subsequent phase I clinical trials (NCT01339871, a phase I study of pazopanib and vorinostat in patients with advanced malignancies; and NCT02042989, a phase I study of ixazomib and vorinostat in patients with advanced <italic>TP53</italic> mutant malignancies) in order to target patients with metastatic <italic>TP53</italic> mutant solid tumors. Our two phase I clinical trials provide preliminary prospective evidence supporting the use of antiangiogenesis-based therapy in patients with <italic>TP53</italic> mutations.</p>
              <p id="Par11">Our phase I trial of pazopanib and vorinostat revealed that the combination therapy was more effective in cancer patients with <italic>TP53</italic> hotspot mutations than in patients without TP53 hotspot mutations<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Many cancers have <italic>TP53</italic> mutations<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, many of which produce mutant p53 gain-of-function proteins, leading to tumorigenesis, tumor development, and metastasis<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. Because they promote tumor growth through VEGF overexpression and increased neovascularization<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and regulate cell cycle arrest, DNA damage repair, cellular senescence, apoptosis, metabolism, stem cell maintenance, tumor invasion, metastasis, and communication with the tumor microenvironment<sup><xref ref-type="bibr" rid="CR35">35</xref>â€“<xref ref-type="bibr" rid="CR37">37</xref></sup>, mutant p53 proteins are potential therapeutic targets<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. To be effective against <italic>TP53</italic> mutant malignancies, a therapy must target many biological pathways simultaneously. The results of our phase I trial of the HDAC inhibitor vorinostat plus the VEGF inhibitor pazopanib support the use of this combination in patients with <italic>TP53</italic> mutant malignancies<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. These agents likely have antitumor activity through their synergistic antiangiogenic effects, facilitation of mutant p53 degradation<sup><xref ref-type="bibr" rid="CR10">10</xref>â€“<xref ref-type="bibr" rid="CR12">12</xref></sup>, and downregulation of VEGF inhibitionâˆ’mediated HIF-1Î± overexpression<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>.</p>
              <p id="Par12">Preclinical studies have shown that proteasome inhibition induces p53-dependent and -independent apoptosis and that HDAC inhibition mediates preferential cytotoxicity towards p53 mutant cells. In addition, combined proteasome and HDAC inhibition has synergistic antitumor effects by modulating epigenetic gene expression<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>, posttranslational modifications<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, and protein degradation in the proteasome and aggresome pathways<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>, thereby increasing cellular stress and apoptosis<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. On the basis of these findings, we conducted a phase I trial of ixazomib and vorinostat in 59 patients with metastatic <italic>TP53</italic> mutant solid tumors, expecting to find that the combination had efficacy against these tumors. However, the combination did not elicit an objective response in any of these patients and was associated with poor PFS and OS. These findings led us to initiate the present study to investigate the role of these therapeutic regimens in patients with <italic>TP53</italic> mutant malignancies by comparing their antitumor activity and associated survival outcomes between the two phase I trials. Among patients with metastatic solid tumors with <italic>TP53</italic> hotspot mutations â€“ particularly patients who had colorectal carcinoma or sarcoma â€“ those treated with pazopanib and vorinostat had a significantly longer median PFS duration and a longer OS duration than did those treated with ixazomib and vorinostat. These findings suggest that vorinostat should be paired with pazopanib, rather than ixazomib, for the treatment of cancers with <italic>TP53</italic> mutations.</p>
              <p id="Par13">The present study yielded several additional insights into the use of vorinostat with pazopanib or ixazomib against metastatic solid tumors with <italic>TP53</italic> mutations. First, although preclinical evidence suggests that HDAC inhibition induces preferential cytotoxicity towards p53 mutant cells, our findings suggest that the use of vorinostat most likely contributed to the high frequencies of dose reduction and patient withdrawal owing to drug toxicity in the two trials. Thus, additional studies to determine whether lower doses of HDAC inhibitors can have meaningful therapeutic effect against p53 mutant cancer cells may be warranted. Second, many patients can be maintained at lower dose levels. There is no statistical relationship between dose level and major clinical outcomes including antitumor responses and survivals. Third, because p53 is at the hub of numerous signaling pathways triggered by a range of cellular stresses, effective therapeutic strategies against malignancies driven by p53 mutations may require several agents simultaneously targeting multiple p53-regulated downstream pathways.</p>
              <p id="Par14">The present study had several potential limitations that could limit the clinical relevance of its findings. First, as with many early clinical trials, the phase I trials we conductedâ€”despite employing eligibility criteria similar to those used in other phase I trials enrolling patients with advanced solid tumors lacking effective standard therapyâ€”were subject to patient selection bias, which may limit the generalizability of our findings to patients with <italic>TP53</italic> mutant malignancies. Second, owing to their small sample sizes, the subgroup analyses could not reliably detect significant differences between groups. Third, because they did not include correlative pharmacokinetics and pharmacodynamics assessments, the phase I trials may not have identified the optimal recommended phase II doses of the drug combinations they tested.</p>
            </sec>
            <sec id="Sec10">
              <title>Patients and Methods</title>
              <sec id="Sec11">
                <title>Trial design and patient enrollment</title>
                <p id="Par15">The trial of pazopanib and vorinostat enrolled patients with metastatic solid tumors from April 2011 to December 2013, whereas the trial of ixazomib and vorinostat enrolled patients with metastatic solid tumors carrying <italic>TP53</italic> hotspot mutations, defined as positive cytoplasmic staining by immunohistochemistry and/or next gene mutation sequencing from July 2014 to February 2017. For both trials, patients were age â‰¥18 years, with a histologically confirmed advanced malignancy and without a standard therapy that improved survival â‰¥3 months. All eligible patients also had measurable or evaluable disease that had progressed prior to enrollment and an Eastern Cooperative Oncology Group performance status score of â‰¥2<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Additional eligibility criteria included adequate marrow function (absolute neutrophil count â‰¥1,000/Î¼l and platelet count â‰¥75,000/Î¼l), a calculated creatinine clearance rate of â‰¥30â€‰ml/min, a total bilirubin level â‰¤1.5 Ã— the upper limit of the normal (ULN), and alanine aminotransferase and aspartate aminotransferase levels â‰¤3 Ã— the ULN. Patients were excluded if they had clinically significant cardiovascular disease; had active uncontrolled central nervous system involvement; had active serious infection requiring systemic antibiotics; had known gastrointestinal disease or other condition that could interfere with swallowing or oral absorption; were pregnant or lactating; had not recovered from previous cancer therapeutics; or were unwilling or unable to give written informed consent. Both trials were conducted at MD Anderson and were approved by MD Andersonâ€™s Institutional Review Board. Informed consent was obtained from all study participants, and all methods were performed in accordance within the relevant guidelines and regulations.</p>
              </sec>
              <sec id="Sec12">
                <title>Evaluation of toxicity and efficacy</title>
                <p id="Par16">Patients who had received at least one dose of any of the study agents were considered evaluable for drug safety. Toxicity severity was graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (<ext-link ext-link-type="uri" xlink:href="http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40">http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40</ext-link>). Dose-limiting toxicity was defined as treatment-related grade 4 hematologic toxicity lasting &gt;1 week; grade 4 nausea or vomiting lasting &gt;3 days despite appropriate medical intervention; grade 4 fatigue or hypertension; or grade 3 or higher non-hematologic toxicity occurring within the initial 28-day treatment cycle. The maximum tolerated dose was defined as the dose level below that at which &gt;33% of patients experienced dose-limiting toxicity.</p>
                <p id="Par17">Patients who received at least one dose of any of the study agents were considered evaluable for drug efficacy. Patients receiving therapy underwent radiographic imaging studies every 8 weeks. We used Response Evaluation Criteria in Solid Tumors 1.1 to assess tumor responses<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
              </sec>
              <sec id="Sec13">
                <title>Molecular assays for <italic>TP53</italic> mutations</title>
                <p id="Par18">Archival formalin-fixed, paraffin-embedded tissue blocks, core biopsy specimens, or surgical resection specimens were used for <italic>TP53</italic> mutation assessment. <italic>TP53</italic> mutation assessment was performed in a Clinical Laboratory Improvement Amendmentâˆ’certified molecular diagnostic laboratory at MD Anderson Cancer Center (for hotspots 2 [1â€“20], 4 [68â€“113], 5 [126â€“138], 5 [149â€“187], 6 [187â€“223], 7 [225â€“258], 8 [263â€“307], and 10 [332â€“367]), as well as at Foundation Medicine (for the entire coding sequence), as described previously<sup><xref ref-type="bibr" rid="CR47">47</xref>â€“<xref ref-type="bibr" rid="CR49">49</xref></sup>.</p>
              </sec>
              <sec id="Sec14">
                <title>Statistical considerations</title>
                <p id="Par19">Both phase I trials followed a modified zone-based 3â€‰+â€‰3 dose-escalation design<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. An additional cohort of up to 3 patients was allowed per dose level as needed for safety assessment. If clinical benefit was observed in patients with a specific type of cancer, a dose expansion cohort of up to 14 patients was permitted at the highest dose level considered to be safe at the time of patient entry, as described previously<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Continuous data were summarized using medians, ranges, and 95% CIs. Categorical data were summarized using frequencies and percentages. Differences in categorical variables were assessed using the Fisher exact test. PFS was defined as the time from the date of initial trial therapy (cycle 1 day 1) to the date of death or tumor progression. OS was defined as the time from the date of initial trial therapy to the date of death or last radiographic assessment. Patients who had no evidence of disease progression or were alive at the end of the study period were censored at the date of last radiographic assessment. The Kaplan-Meier method was used to estimate PFS and OS, and log-rank tests were used to compare PFS and OS distributions between the treatment groups. Differences between the treatment groups were assessed using two-sided t-tests; <italic>p</italic> valuesâ€‰&lt;â€‰0.05 were considered significant. Statistical analyses were performed using SPSS Statistics, version 24 (IBM, Armonk, NY).</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec15">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41598_2020_58366_MOESM1_ESM.docx">
                      <caption>
                        <p>Supplementary information</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisherâ€™s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p>is available for this paper at 10.1038/s41598-020-58366-z.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors thank the patients who participated in the clinical trials and their families; the clinical research personnel and clinical staff in MD Andersonâ€™s Clinical Center for Targeted Therapy for their comprehensive patient care and service; and Joe Munch in Scientific Publications, Research Medical Library, at MD Anderson for editing the manuscript. The authors also thank Takeda Pharmaceutical for supporting the phase I trial of ixazomib and vorinostat through a grant (to SF) and by providing ixazomib.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>Yudong Wang: Data collection, analysis, and interpretation; manuscript writing; final manuscript approval; and provision of study materials and patients. Filip Janku: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. Sarina Piha-Paul: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. Kenneth Hess: Data collection, assembly, analysis, and interpretation. Russell Broaddus: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. Lidong Liu: Data collection and assembly. Naiyi Shi: Data collection and assembly. Michael Overman: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. Scott Kopetz: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. Vivek Subbiah: Data collection, analysis, and interpretation; final manuscript approval; and provision of study materials and patients. Aung Naing: Study conception and design; data collection, analysis, and interpretation; manuscript writing; final manuscript approval; and provision of study materials and patients. David Hong: Manuscript editing and provision of study materials and patients. Apostolia-Maria Tsimberidou: Data collection, analysis, and interpretation; manuscript writing; final manuscript approval; and provision of study materials and patients. Daniel Karp: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. James Yao: Data collection, manuscript writing, final manuscript approval, and provision of study materials and patients. Siqing Fu: Study conception and design; data collection, analysis, and interpretation; manuscript writing; final manuscript approval; and provision of study materials and patients.</p>
            </notes>
            <notes notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par21">The competing and non-financial interests of the authors are listed below. This study used MD Andersonâ€™s Clinical Research Facility, which is supported by the NIH through MD Andersonâ€™s Cancer Center Support Grant (P30CA016672). MD Anderson receives funds from Takeda Pharmaceutical Company and the National Institutes of Health/NCI (grant #P30CA016672), which in turn funded Dr. Fuâ€™s research for this manuscript. Drs. Vivek Subbiah and David Hong have both received clinical trial research funding from Takeda Pharmaceutical Company and the NIH/NCI through MD Anderson. Drs. Filip Janku, Sarina Piha-Paul, Michael Overman, Russell Broaddus, Scott Kopetz, Aung Naing, Apostolia-Maria Tsimberidou, Daniel Karp, and James Yao receive partial funding for their clinic research from the NIH/NCI (grant #P30CA016672). All other authors have no competing interests to declare.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Paez-Ribes</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis</article-title>
                  <source>Cancer Cell</source>
                  <year>2009</year>
                  <volume>15</volume>
                  <fpage>220</fpage>
                  <lpage>231</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccr.2009.01.027</pub-id>
                  <?supplied-pmid 19249680?>
                  <pub-id pub-id-type="pmid">19249680</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ebos</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis</article-title>
                  <source>Cancer Cell</source>
                  <year>2009</year>
                  <volume>15</volume>
                  <fpage>232</fpage>
                  <lpage>239</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccr.2009.01.021</pub-id>
                  <?supplied-pmid 19249681?>
                  <pub-id pub-id-type="pmid">19249681</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Simonsen</surname>
                      <given-names>TG</given-names>
                    </name>
                    <name>
                      <surname>Gaustad</surname>
                      <given-names>JV</given-names>
                    </name>
                    <name>
                      <surname>Rofstad</surname>
                      <given-names>EK</given-names>
                    </name>
                  </person-group>
                  <article-title>Development of hypoxia in a preclinical model of tumor micrometastases</article-title>
                  <source>Int. J. Radiat. Oncol. Biol. Phys.</source>
                  <year>2010</year>
                  <volume>76</volume>
                  <fpage>879</fpage>
                  <lpage>888</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.09.045</pub-id>
                  <?supplied-pmid 20159362?>
                  <pub-id pub-id-type="pmid">20159362</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fath</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha</article-title>
                  <source>J. Biol. Chem.</source>
                  <year>2006</year>
                  <volume>281</volume>
                  <fpage>13612</fpage>
                  <lpage>13619</lpage>
                  <pub-id pub-id-type="doi">10.1074/jbc.M600456200</pub-id>
                  <?supplied-pmid 16543236?>
                  <pub-id pub-id-type="pmid">16543236</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>SH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Regulation of the HIF-1alpha stability by histone deacetylases</article-title>
                  <source>Oncol. Rep.</source>
                  <year>2007</year>
                  <volume>17</volume>
                  <fpage>647</fpage>
                  <lpage>651</lpage>
                  <?supplied-pmid 17273746?>
                  <pub-id pub-id-type="pmid">17273746</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keith</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Simon</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>Hypoxia-inducible factors, stem cells, and cancer</article-title>
                  <source>Cell</source>
                  <year>2007</year>
                  <volume>129</volume>
                  <fpage>465</fpage>
                  <lpage>472</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cell.2007.04.019</pub-id>
                  <?supplied-pmid 17482542?>
                  <pub-id pub-id-type="pmid">17482542</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loges</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mazzone</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hohensinner</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Carmeliet</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited</article-title>
                  <source>Cancer Cell</source>
                  <year>2009</year>
                  <volume>15</volume>
                  <fpage>167</fpage>
                  <lpage>170</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccr.2009.02.007</pub-id>
                  <?supplied-pmid 19249675?>
                  <pub-id pub-id-type="pmid">19249675</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sen</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Kumari</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>MI</given-names>
                    </name>
                    <name>
                      <surname>Das</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress</article-title>
                  <source>Mol. Cell</source>
                  <year>2013</year>
                  <volume>52</volume>
                  <fpage>406</fpage>
                  <lpage>420</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.molcel.2013.09.003</pub-id>
                  <?supplied-pmid 24120667?>
                  <pub-id pub-id-type="pmid">24120667</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Marks</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Richon</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kelly</surname>
                      <given-names>WK</given-names>
                    </name>
                  </person-group>
                  <article-title>Histone deacetylase inhibitors</article-title>
                  <source>Adv. Cancer Res.</source>
                  <year>2004</year>
                  <volume>91</volume>
                  <fpage>137</fpage>
                  <lpage>168</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0065-230X(04)91004-4</pub-id>
                  <?supplied-pmid 15327890?>
                  <pub-id pub-id-type="pmid">15327890</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Marchenko</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Moll</surname>
                      <given-names>UM</given-names>
                    </name>
                  </person-group>
                  <article-title>SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis</article-title>
                  <source>Cell Death Differ.</source>
                  <year>2011</year>
                  <volume>18</volume>
                  <fpage>1904</fpage>
                  <lpage>1913</lpage>
                  <pub-id pub-id-type="doi">10.1038/cdd.2011.71</pub-id>
                  <?supplied-pmid 21637290?>
                  <pub-id pub-id-type="pmid">21637290</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yan</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>X</given-names>
                    </name>
                  </person-group>
                  <article-title>Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8</article-title>
                  <source>Oncogene</source>
                  <year>2012</year>
                  <volume>32</volume>
                  <issue>5</issue>
                  <fpage>599</fpage>
                  <lpage>609</lpage>
                  <pub-id pub-id-type="doi">10.1038/onc.2012.81</pub-id>
                  <?supplied-pmid 22391568?>
                  <pub-id pub-id-type="pmid">22391568</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blagosklonny</surname>
                      <given-names>MV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors</article-title>
                  <source>Cancer Res.</source>
                  <year>2005</year>
                  <volume>65</volume>
                  <fpage>7386</fpage>
                  <lpage>7392</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3433</pub-id>
                  <?supplied-pmid 16103091?>
                  <pub-id pub-id-type="pmid">16103091</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joshi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bhanot</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Borresen-Dale</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Kristensen</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway</article-title>
                  <source>Br. J. Cancer</source>
                  <year>2012</year>
                  <volume>107</volume>
                  <fpage>1722</fpage>
                  <lpage>1728</lpage>
                  <pub-id pub-id-type="doi">10.1038/bjc.2012.461</pub-id>
                  <?supplied-pmid 23079576?>
                  <pub-id pub-id-type="pmid">23079576</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Montero</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Abreu</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Tonino</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas</article-title>
                  <source>J. cancer Res. Clin. Oncol.</source>
                  <year>2008</year>
                  <volume>134</volume>
                  <fpage>193</fpage>
                  <lpage>201</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00432-007-0270-5</pub-id>
                  <?supplied-pmid 17636327?>
                  <pub-id pub-id-type="pmid">17636327</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ravi</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha</article-title>
                  <source>Genes. Dev.</source>
                  <year>2000</year>
                  <volume>14</volume>
                  <fpage>34</fpage>
                  <lpage>44</lpage>
                  <?supplied-pmid 10640274?>
                  <pub-id pub-id-type="pmid">10640274</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Said</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Characteristics and survival of patients with advanced cancer and p53 mutations</article-title>
                  <source>Oncotarget</source>
                  <year>2014</year>
                  <volume>5</volume>
                  <fpage>3871</fpage>
                  <lpage>3879</lpage>
                  <pub-id pub-id-type="doi">10.18632/oncotarget.2004</pub-id>
                  <?supplied-pmid 25003695?>
                  <pub-id pub-id-type="pmid">25003695</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience</article-title>
                  <source>Cancer Med.</source>
                  <year>2016</year>
                  <volume>5</volume>
                  <fpage>3437</fpage>
                  <lpage>3444</lpage>
                  <pub-id pub-id-type="doi">10.1002/cam4.956</pub-id>
                  <?supplied-pmid 27882721?>
                  <pub-id pub-id-type="pmid">27882721</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer</article-title>
                  <source>Oncotarget</source>
                  <year>2017</year>
                  <volume>8</volume>
                  <fpage>33796</fpage>
                  <lpage>33806</lpage>
                  <?supplied-pmid 28430579?>
                  <pub-id pub-id-type="pmid">28430579</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer</article-title>
                  <source>Oncotarget</source>
                  <year>2018</year>
                  <volume>9</volume>
                  <fpage>33258</fpage>
                  <lpage>33270</lpage>
                  <?supplied-pmid 30279957?>
                  <pub-id pub-id-type="pmid">30279957</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fraisl</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Mazzone</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schmidt</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Carmeliet</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Regulation of angiogenesis by oxygen and metabolism</article-title>
                  <source>Dev. Cell</source>
                  <year>2009</year>
                  <volume>16</volume>
                  <fpage>167</fpage>
                  <lpage>179</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.devcel.2009.01.003</pub-id>
                  <?supplied-pmid 19217420?>
                  <pub-id pub-id-type="pmid">19217420</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mazumdar</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dondeti</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Simon</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>Hypoxia-inducible factors in stem cells and cancer</article-title>
                  <source>J. Cell Mol. Med.</source>
                  <year>2009</year>
                  <volume>13</volume>
                  <fpage>4319</fpage>
                  <lpage>4328</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00963.x</pub-id>
                  <?supplied-pmid 19900215?>
                  <pub-id pub-id-type="pmid">19900215</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dokmanovic</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Histone deacetylase inhibitors selectively suppress expression of HDAC7</article-title>
                  <source>Mol. cancer therapeutics</source>
                  <year>2007</year>
                  <volume>6</volume>
                  <fpage>2525</fpage>
                  <lpage>2534</lpage>
                  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0251</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Semenza</surname>
                      <given-names>GL</given-names>
                    </name>
                  </person-group>
                  <article-title>HIF-1: upstream and downstream of cancer metabolism</article-title>
                  <source>Curr. Opin. Genet. Dev.</source>
                  <year>2010</year>
                  <volume>20</volume>
                  <fpage>51</fpage>
                  <lpage>56</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.gde.2009.10.009</pub-id>
                  <?supplied-pmid 19942427?>
                  <pub-id pub-id-type="pmid">19942427</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richardson</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>KC</given-names>
                    </name>
                  </person-group>
                  <article-title>Bortezomib: a novel therapy approved for multiple myeloma</article-title>
                  <source>Clin. Adv. Hematol. Oncol.</source>
                  <year>2003</year>
                  <volume>1</volume>
                  <fpage>596</fpage>
                  <lpage>600</lpage>
                  <?supplied-pmid 16258456?>
                  <pub-id pub-id-type="pmid">16258456</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <mixed-citation publication-type="other">Pili, R. <italic>et al</italic>. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in pretreated patients with renal cell carcinoma: Safety, efficacy, and pharmacodynamic results. <italic>Genitourinary Cancers Symposium</italic>, Abstract 350 (2010).</mixed-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <mixed-citation publication-type="other">Dasari, A. <italic>et al</italic>. A phase I safety and tolerability study of vorinostat (V) in combination with sorafenib (S) in patients with advanced solid tumors, with exploration of two tumor-type specific expanded cohorts at the recommended phase II dose (renal and non-small cell lung carcinoma). <italic>Journal of Clinical Oncology</italic>, 28:15s, Suppl; abstract 2562 (2010).</mixed-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ellis</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Hammers</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Pili</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting tumor angiogenesis with histone deacetylase inhibitors</article-title>
                  <source>Cancer Lett.</source>
                  <year>2009</year>
                  <volume>280</volume>
                  <fpage>145</fpage>
                  <lpage>153</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.canlet.2008.11.012</pub-id>
                  <?supplied-pmid 19111391?>
                  <pub-id pub-id-type="pmid">19111391</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fu</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation</article-title>
                  <source>Ann. Oncol.</source>
                  <year>2015</year>
                  <volume>26</volume>
                  <fpage>1012</fpage>
                  <lpage>1018</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdv066</pub-id>
                  <?supplied-pmid 25669829?>
                  <pub-id pub-id-type="pmid">25669829</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shen</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy</article-title>
                  <source>Clin. Cancer Res.</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <fpage>1561</fpage>
                  <lpage>1567</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3040</pub-id>
                  <?supplied-pmid 22307140?>
                  <pub-id pub-id-type="pmid">22307140</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vousden</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Ryan</surname>
                      <given-names>KM</given-names>
                    </name>
                  </person-group>
                  <article-title>p53 and metabolism</article-title>
                  <source>Nat. Rev. Cancer</source>
                  <year>2009</year>
                  <volume>9</volume>
                  <fpage>691</fpage>
                  <lpage>700</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrc2715</pub-id>
                  <?supplied-pmid 19759539?>
                  <pub-id pub-id-type="pmid">19759539</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Green</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Kroemer</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Cytoplasmic functions of the tumour suppressor p53</article-title>
                  <source>Nat.</source>
                  <year>2009</year>
                  <volume>458</volume>
                  <fpage>1127</fpage>
                  <lpage>1130</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature07986</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Muller</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Vousden</surname>
                      <given-names>KH</given-names>
                    </name>
                  </person-group>
                  <article-title>Mutant p53 in cancer: new functions and therapeutic opportunities</article-title>
                  <source>Cancer Cell</source>
                  <year>2014</year>
                  <volume>25</volume>
                  <fpage>304</fpage>
                  <lpage>317</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccr.2014.01.021</pub-id>
                  <?supplied-pmid 24651012?>
                  <pub-id pub-id-type="pmid">24651012</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leroy</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis</article-title>
                  <source>Nucleic acids Res.</source>
                  <year>2013</year>
                  <volume>41</volume>
                  <fpage>D962</fpage>
                  <lpage>969</lpage>
                  <pub-id pub-id-type="doi">10.1093/nar/gks1033</pub-id>
                  <?supplied-pmid 23161690?>
                  <pub-id pub-id-type="pmid">23161690</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ambs</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells</article-title>
                  <source>Nat. Med.</source>
                  <year>1998</year>
                  <volume>4</volume>
                  <fpage>1371</fpage>
                  <lpage>1376</lpage>
                  <pub-id pub-id-type="doi">10.1038/3957</pub-id>
                  <?supplied-pmid 9846573?>
                  <pub-id pub-id-type="pmid">9846573</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yamakuchi</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis</article-title>
                  <source>Proc. Natl Acad. Sci. USA</source>
                  <year>2010</year>
                  <volume>107</volume>
                  <fpage>6334</fpage>
                  <lpage>6339</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.0911082107</pub-id>
                  <?supplied-pmid 20308559?>
                  <pub-id pub-id-type="pmid">20308559</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vogelstein</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kinzler</surname>
                      <given-names>KW</given-names>
                    </name>
                  </person-group>
                  <article-title>Cancer genes and the pathways they control</article-title>
                  <source>Nat. Med.</source>
                  <year>2004</year>
                  <volume>10</volume>
                  <fpage>789</fpage>
                  <lpage>799</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm1087</pub-id>
                  <?supplied-pmid 15286780?>
                  <pub-id pub-id-type="pmid">15286780</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bieging</surname>
                      <given-names>KT</given-names>
                    </name>
                    <name>
                      <surname>Mello</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Attardi</surname>
                      <given-names>LD</given-names>
                    </name>
                  </person-group>
                  <article-title>Unravelling mechanisms of p53-mediated tumour suppression</article-title>
                  <source>Nat. Rev. Cancer</source>
                  <year>2014</year>
                  <volume>14</volume>
                  <fpage>359</fpage>
                  <lpage>370</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrc3711</pub-id>
                  <?supplied-pmid 24739573?>
                  <pub-id pub-id-type="pmid">24739573</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Said</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy</article-title>
                  <source>Oncotarget</source>
                  <year>2013</year>
                  <volume>4</volume>
                  <fpage>705</fpage>
                  <lpage>714</lpage>
                  <pub-id pub-id-type="doi">10.18632/oncotarget.974</pub-id>
                  <?supplied-pmid 23670029?>
                  <pub-id pub-id-type="pmid">23670029</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mitsiades</surname>
                      <given-names>CS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications</article-title>
                  <source>Proc. Natl Acad. Sci. USA</source>
                  <year>2004</year>
                  <volume>101</volume>
                  <fpage>540</fpage>
                  <lpage>545</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.2536759100</pub-id>
                  <?supplied-pmid 14695887?>
                  <pub-id pub-id-type="pmid">14695887</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mitsiades</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular sequelae of histone deacetylase inhibition in human malignant B cells</article-title>
                  <source>Blood</source>
                  <year>2003</year>
                  <volume>101</volume>
                  <fpage>4055</fpage>
                  <lpage>4062</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2002-11-3514</pub-id>
                  <?supplied-pmid 12531799?>
                  <pub-id pub-id-type="pmid">12531799</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mitsiades</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular sequelae of proteasome inhibition in human multiple myeloma cells</article-title>
                  <source>Proc. Natl Acad. Sci. USA</source>
                  <year>2002</year>
                  <volume>99</volume>
                  <fpage>14374</fpage>
                  <lpage>14379</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.202445099</pub-id>
                  <?supplied-pmid 12391322?>
                  <pub-id pub-id-type="pmid">12391322</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hideshima</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>KC</given-names>
                    </name>
                  </person-group>
                  <article-title>Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma</article-title>
                  <source>Mol. Cancer Ther.</source>
                  <year>2011</year>
                  <volume>10</volume>
                  <fpage>2034</fpage>
                  <lpage>2042</lpage>
                  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0433</pub-id>
                  <?supplied-pmid 22072815?>
                  <pub-id pub-id-type="pmid">22072815</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Catley</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells</article-title>
                  <source>Blood</source>
                  <year>2006</year>
                  <volume>108</volume>
                  <fpage>3441</fpage>
                  <lpage>3449</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2006-04-016055</pub-id>
                  <?supplied-pmid 16728695?>
                  <pub-id pub-id-type="pmid">16728695</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pei</surname>
                      <given-names>XY</given-names>
                    </name>
                    <name>
                      <surname>Dai</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Grant</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors</article-title>
                  <source>Clin. cancer research: an. Off. J. Am. Assoc. Cancer Res.</source>
                  <year>2004</year>
                  <volume>10</volume>
                  <fpage>3839</fpage>
                  <lpage>3852</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-03-0561</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oken</surname>
                      <given-names>MM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Toxicity and response criteria of the Eastern Cooperative Oncology Group</article-title>
                  <source>Am. J. Clin. Oncol.</source>
                  <year>1982</year>
                  <volume>5</volume>
                  <fpage>649</fpage>
                  <lpage>655</lpage>
                  <pub-id pub-id-type="doi">10.1097/00000421-198212000-00014</pub-id>
                  <?supplied-pmid 7165009?>
                  <pub-id pub-id-type="pmid">7165009</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eisenhauer</surname>
                      <given-names>EA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>
                  <source>Eur. J. Cancer</source>
                  <year>2009</year>
                  <volume>45</volume>
                  <fpage>228</fpage>
                  <lpage>247</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
                  <?supplied-pmid 19097774?>
                  <pub-id pub-id-type="pmid">19097774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>RR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes</article-title>
                  <source>J. Mol. diagnostics: JMD</source>
                  <year>2013</year>
                  <volume>15</volume>
                  <fpage>607</fpage>
                  <lpage>622</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jmoldx.2013.05.003</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frampton</surname>
                      <given-names>GM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title>
                  <source>Nat. Biotechnol.</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <fpage>1023</fpage>
                  <lpage>1031</lpage>
                  <pub-id pub-id-type="doi">10.1038/nbt.2696</pub-id>
                  <?supplied-pmid 24142049?>
                  <pub-id pub-id-type="pmid">24142049</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>MacConaill</surname>
                      <given-names>LE</given-names>
                    </name>
                  </person-group>
                  <article-title>Existing and emerging technologies for tumor genomic profiling</article-title>
                  <source>J. Clin. oncology: Off. J. Am. Soc. Clin. Oncol.</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <fpage>1815</fpage>
                  <lpage>1824</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2012.46.5948</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Biswas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Oki</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Issa</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Berry</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>A parallel phase I/II clinical trial design for combination therapies</article-title>
                  <source>Biometrics</source>
                  <year>2007</year>
                  <volume>63</volume>
                  <fpage>429</fpage>
                  <lpage>436</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1541-0420.2006.00685.x</pub-id>
                  <?supplied-pmid 17688495?>
                  <pub-id pub-id-type="pmid">17688495</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moroney</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity</article-title>
                  <source>Clin. cancer research: an. Off. J. Am. Assoc. Cancer Res.</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <fpage>5796</fpage>
                  <lpage>5805</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1158</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
